Video transcript
Hello from Milan! We are with Dr. Giuseppe Curigliano, who is a world-renowned expert in cancer treatment and new cancer drug development. We are going to discuss today the advances in the treatment of different breast cancer types, like HER2 negative and positive breast cancers, triple-negative breast cancer, early and metastatic breast cancers. We will also talk about advances in immunotherapy and the challenges of new drug development in cancer treatment. Let me give you an overview of the professional career of Professor Giuseppe Curigliano. Dr. Giuseppe Curigliano is a Director of New Drugs and Early Drug Development for Innovative Therapies at the European Institute of Oncology in Milan, Italy. He is a Professor of Medical Oncology at the University of Milano. Dr. Giuseppe Curigliano leads clinical studies and research programs concerning the Phase 0, I, and early Phase II treatments in metastatic breast cancer and solid tumors. Dr. Giuseppe Curigliano obtained his MD from the University of Rome in Italy. He completed his Ph.D. in Medical Pathophysiology and Clinical Pharmacology at the University of Pisa. Dr. Giuseppe Curigliano did a fellowship in oncology and clinical immunology at South Carolina Medical School, Charleston, United States, research at the National Cancer Institute, in the Bethesda United States. He also worked at Cancer Center at Columbia University in New York. Dr. Giuseppe Curigliano was a visiting scientist at Dana Farber Cancer Center, Harvard Medical School in Boston. Dr. Giuseppe Curigliano was also a Co-Director of the Division of Medical Oncology, European Institute of Oncology in Milan, Italy. Dr. Giuseppe Curigliano has been a member of the Scientific Advisory Council of the International Breast Cancer Study Group and a member of the Scientific Advisory Council of the Breast International Group.
Dr. Giuseppe Curigliano was named “Expert Clinical Assessor for Oncology” at the European Medicines Agency. He was the editor of the Project START (State of the Art Oncology in Europe). He is a member of the Breast Faculty of the European Society of Medical Oncology, where he served as the Chair of the Guidelines Committee and is a Council Member. Dr. Giuseppe Curigliano is on the faculty of the European School of Oncology and the faculty of the St Gallen Early Breast Cancer Conference. Dr. Curigliano is the co-founder and scientific secretary of the International Cardio-Oncology Society. Dr. Giuseppe Curigliano is a member of the editorial boards of the highly cited international clinical oncology journals: Journal of Clinical Oncology in the US and Annals of Oncology in Europe. He is also a co-Editor in Chief of The Breast, Co-Editor in Chief of Cancer Treatment Reviews, Associate Editor of the European Journal of Cancer. Dr. Giuseppe Curigliano was awarded the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017. Dr. Giuseppe Curigliano has authored and co-authored over 480 peer-reviewed publications in international medical journals and presented numerous talks at international conferences on cancer research and treatment. Dr. Giuseppe Curigliano, hello and welcome!